A novel, "double-clamp" binding mode for human heme oxygenase-1 inhibition

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Rahman, Mona N ^a   Vlahakis, Jason Z ^a   Vukomanovic, Dragic ^a   Lee, Wallace ^a   Szarek, Walter A ^a   Nakatsu, Kanji ^a   Jia, Zongchao ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1H IMIDAZOL 1 YL) 4,4 DIPHENYL 2 BUTANONE; 1 (ADAMANTAN 1 YL) 2 (1H IMIDAZOL 1 YL)ETHANONE; 2 (2 PHENYLETHYL) 2 [(1H IMIDAZOL 1 YL)METHYL] 1,3 DIOXOLANE; 2 [2 (4 CHLOROPHENYL)ETHYL] 2 [(1H IMIDAZOL 1 YL)METHYL] 1,3 DIOXOLANE; 2 [2 (4 CHLOROPHENYL)ETHYL] 2 [(1H IMIDAZOL 1 YL)METHYL] 4 [[(5 TRIFLUOROMETHYLPYRIDIN 2 YL)THIO]METHYL] 1,3 DIOXOLANE; 4 PHENYL 1 (1,2,4 1H TRIAZOL 1 YL) 2 BUTANONE; 4 PHENYL 1 (1H IMIDAZOL 1 YL) 2 BUTANONE; AZALANSTAT; CARBON MONOXIDE; HEME OXYGENASE 1; HEME OXYGENASE INHIBITOR; PHENYL GROUP; QC 15; QC 308; QC 57; QC 65; QC 80; QC 82; QC 86; UNCLASSIFIED DRUG; ENZYME INHIBITOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING; DRUG POTENCY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME BINDING; ENZYME INHIBITION; ENZYME STRUCTURE; HYDROPHOBICITY; IC 50; MICROSOME; NONHUMAN; SPLEEN MICROSOME; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; HUMAN; METABOLISM; PROTEIN BINDING; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; X RAY CRYSTALLOGRAPHY;

RATTUS;

CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HEME OXYGENASE-1; HUMANS; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY;

EID: 84855998406     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029514     Document Type: Article

References (60)

1. Tenhunen R, Marver HS, Schmid R, (1969) Microsomal heme oxygenase. Characterization of the enzyme. J Biol Chem 244: 6388-6394.
2. Vreman HJ, Wong RJ, Stevenson DK, (2002) Carbon Monoxide and Cardiovascular Function Boca Raton, London, New York, Washington CRC Press.
3. Maines MD, (1997) The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 37: 517-554.
4. Hayashi S, Omata Y, Sakamoto H, Higashimoto Y, Hara T, et al. (2004) Characterization of rat heme oxygenase-3 gene. Implication of processed pseudogenes derived from heme oxygenase-2 gene. Gene 336: 241-250.
5. Ryter SW, Alam J, Choi AM, (2006) Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev 86: 583-650.
6. Lee TS, Chau LY, (2002) Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat Med 8: 240-246.
7. Lee TS, Tsai HL, Chau LY, (2003) Induction of heme oxygenase-1 expression in murine macrophages is essential for the anti-inflammatory effect of low dose 15-deoxy-Delta 12,14-prostaglandin J2. J Biol Chem 278: 19325-19330.
8. Imuta N, Hori O, Kitao Y, Tabata Y, Yoshimoto T, et al. (2007) Hypoxia-mediated induction of heme oxygenase type I and carbon monoxide release from astrocytes protects nearby cerebral neurons from hypoxia-mediated apoptosis. Antioxid Redox Signal 9: 543-552.
9. Farrera JA, Jauma A, Ribo JM, Peire MA, Parellada PP, et al. (1994) The antioxidant role of bile pigments evaluated by chemical tests. Bioorg Med Chem 2: 181-185.
10. Asad SF, Singh S, Ahmad A, Khan NU, Hadi SM, (2001) Prooxidant and antioxidant activities of bilirubin and its metabolic precursor biliverdin: a structure-activity study. Chem Biol Interact 137: 59-74 S0009279701002095 [pii].
11. Minetti M, Mallozzi C, Di Stasi AM, Pietraforte D, (1998) Bilirubin is an effective antioxidant of peroxynitrite-mediated protein oxidation in human blood plasma. Arch Biochem Biophys 352: 165-174 S0003-9861(98)90584-7 [pii];10.1006/abbi.1998.0584 [doi].
12. Gozzelino R, Jeney V, Soares MP, (2010) Mechanisms of cell protection by heme oxygenase-1. Annu Rev Pharmacol Toxicol 50: 323-354 10.1146/annurev.pharmtox.010909.105600 [doi].
13. Maines MD, Abrahamsson PA, (1996) Expression of heme oxygenase-1 (HSP32) in human prostate: normal, hyperplastic, and tumor tissue distribution. Urology 47: 727-733 S0090-4295(96)00010-6 [pii].
14. Berberat PO, Dambrauskas Z, Gulbinas A, Giese T, Giese N, et al. (2005) Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clin Cancer Res 11: 3790-3798 11/10/3790 [pii];10.1158/1078-0432.CCR-04-2159 [doi].
15. Nowis D, Legat M, Grzela T, Niderla J, Wilczek E, et al. (2006) Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. Oncogene 25: 3365-3374 1209378 [pii];10.1038/sj.onc.1209378 [doi].
16. Luo D, Vincent SR, (1994) Metalloporphyrins inhibit nitric oxide-dependent cGMP formation in vivo. Eur J Pharmacol 267: 263-267.
17. Meffert MK, Haley JE, Schuman EM, Schulman H, Madison DV, (1994) Inhibition of hippocampal heme oxygenase, nitric oxide synthase, and long-term potentiation by metalloporphyrins. Neuron 13: 1225-1233.
18. Grundemar L, Ny L, (1997) Pitfalls using metalloporphyrins in carbon monoxide research. Trends Pharmacol Sci 18: 193-195.
19. Appleton SD, Chretien ML, McLaughlin BE, Vreman HJ, Stevenson DK, et al. (1999) Selective inhibition of heme oxygenase, without inhibition of nitric oxide synthase or soluble guanylyl cyclase, by metalloporphyrins at low concentrations. Drug Metab Dispos 27: 1214-1219.
20. DeNagel DC, Verity AN, Madden FE, Yang CO, Sangameswaran L, et al. (1998) Identification of non-porphyrin inhibitors of heme oxygenase-1. Neuroscience 24: 2058.
21. Kinobe RT, Vlahakis JZ, Vreman HJ, Stevenson DK, Brien JF, et al. (2006) Selectivity of imidazole-dioxolane compounds for in vitro inhibition of microsomal haem oxygenase isoforms. Br J Pharmacol 147: 307-315.
22. Hum M, McLaughlin BE, Roman G, Vlahakis JZ, Szarek WA, et al. (2010) The effects of azole-based heme oxygenase inhibitors on rat cytochromes P450 2E1 and 3A1/2 and human cytochromes P450 3A4 and 2D6. J Pharmacol Exp Ther 334: 981-987 jpet.110.168492 [pii];10.1124/jpet.110.168492 [doi].
23. Roman G, Riley JG, Vlahakis JZ, Kinobe RT, Brien JF, et al. (2007) Heme oxygenase inhibition by 2-oxy-substituted 1-(1H-imidazol-1-yl)-4-phenylbutanes: effect of halogen substitution in the phenyl ring. Bioorg Med Chem 15: 3225-3234.
24. Vlahakis JZ, Kinobe RT, Bowers RJ, Brien JF, Nakatsu K, et al. (2006) Imidazole-dioxolane compounds as isozyme-selective heme oxygenase inhibitors. J Med Chem 49: 4437-4441.
25. Vlahakis JZ, Kinobe RT, Bowers RJ, Brien JF, Nakatsu K, et al. (2005) Synthesis and evaluation of azalanstat analogues as heme oxygenase inhibitors. Bioorg Med Chem Lett 15: 1457-1461.
26. Vlahakis JZ, Hum M, Rahman MN, Jia Z, Nakatsu K, et al. (2009) Synthesis and evaluation of imidazole-dioxolane compounds as selective heme oxygenase inhibitors: effect of substituents at the 4-position of the dioxolane ring. Bioorg Med Chem 17: 2461-2475.
27. Roman G, Rahman MN, Vukomanovic D, Jia Z, Nakatsu K, et al. (2010) Heme oxygenase inhibition by 2-oxy-substituted 1-azolyl-4-phenylbutanes: effect of variation of the azole moiety. X-ray crystal structure of human heme oxygenase-1 in complex with 4-phenyl-1-(1H-1,2,4-triazol-1-yl)-2-butanone. Chem Biol Drug Des 75: 68-90 JPP909 [pii];10.1111/j.1747-0285.2009.00909.x [doi].
28. Di FL, Totani L, Dovizio M, Piccoli A, Di FA, et al. (2009) Induction of prostacyclin by steady laminar shear stress suppresses tumor necrosis factor-alpha biosynthesis via heme oxygenase-1 in human endothelial cells. Circ Res 104: 506-513 CIRCRESAHA.108.191114 [pii];10.1161/CIRCRESAHA.108.191114 [doi].
29. Rahman MN, Vlahakis JZ, Roman G, Vukomanovic D, Szarek WA, et al. (2010) Structural characterization of human heme oxygenase-1 in complex with azole-based inhibitors. J Inorg Biochem 104: 324-330 S0162-0134(09)00259-1 [pii];10.1016/j.jinorgbio.2009.10.011 [doi].
30. Rahman MN, Vlahakis JZ, Szarek WA, Nakatsu K, Jia Z, (2008) X-ray crystal structure of human heme oxygenase-1 in complex with 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone: a common binding mode for imidazole-based heme oxygenase-1 inhibitors. J Med Chem 51: 5943-5952.
31. Rahman MN, Vlahakis JZ, Vukomanovic D, Szarek WA, Nakatsu K, et al. (2009) X-ray crystal structure of human heme oxygenase-1 with (2R,4S)-2-[2-(4-chlorophenyl)ethyl]-2-[(1H-imidazol-1-yl)methyl]-4[((5-tri fluoromethylpyridin-2-yl)thio)methyl]-1,3-dioxolane: a novel, inducible binding mode. J Med Chem 52: 4946-4950.
32. Sugishima M, Higashimoto Y, Oishi T, Takahashi H, Sakamoto H, et al. (2007) X-ray crystallographic and biochemical characterization of the inhibitory action of an imidazole-dioxolane compound on heme oxygenase. Biochemistry 46: 1860-1867.
33. Vlahakis JZ, Rahman MN, Roman G, Jia Z, Nakatsu K, et al. (2010) Rapid, convenient method for screening imidazole-containing compounds for heme oxygenase inhibition. J Pharmacol Toxicol Methods S1056-8719(10)00088-2 [pii];10.1016/j.vascn.2010.05.015 [doi].
34. Vukomanovic D, McLaughlin B, Rahman MN, Vlahakis JZ, Roman G, et al. (2010) Recombinant truncated and microsomal heme oxygenase-1 and-2: differential sensitivity to inhibitors. Can J Physiol Pharmacol 88: 480-486 y10-004 [pii];10.1139/y10-004 [doi].
35. Lad L, Schuller DJ, Shimizu H, Friedman J, Li H, et al. (2003) Comparison of the heme-free and-bound crystal structures of human heme oxygenase-1. J Biol Chem 278: 7834-7843.
36. Schuller DJ, Wilks A, Ortiz de Montellano PR, Poulos TL, (1999) Crystal structure of human heme oxygenase-1. Nat Struct Biol 6: 860-867.
37. Schuller DJ, Wilks A, Ortiz de Montellano PR, Poulos TL, (1998) Crystallization of recombinant human heme oxygenase-1. Protein Sci 7: 1836-1838.
38. Bianchetti CM, Yi L, Ragsdale SW, Phillips GN Jr, (2007) Comparison of apo- and heme-bound crystal structures of a truncated human heme oxygenase-2. J Biol Chem 282: 37624-37631.
39. Huber WJ III, Backes WL, (2007) Expression and characterization of full-length human heme oxygenase-1: the presence of intact membrane-binding region leads to increased binding affinity for NADPH cytochrome P450 reductase. Biochemistry 46: 12212-12219.
40. Huber WJ III, Marohnic CC, Peters M, Alam J, Reed JR, et al. (2009) Measurement of membrane-bound human heme oxygenase-1 activity using a chemically defined assay system. Drug Metab Dispos 37: 857-864.
41. Huber WJ III, Scruggs BA, Backes WL, (2009) C-Terminal membrane spanning region of human heme oxygenase-1 mediates a time-dependent complex formation with cytochrome P450 reductase. Biochemistry 48: 190-197.
42. Lin Q, Weis S, Yang G, Weng YH, Helston R, et al. (2007) Heme oxygenase-1 protein localizes to the nucleus and activates transcription factors important in oxidative stress. J Biol Chem 282: 20621-20633 M607954200 [pii];10.1074/jbc.M607954200 [doi].
43. Huang TJ, McCoubrey WK Jr, Maines MD, (2001) Heme oxygenase-2 interaction with metalloporphyrins: function of heme regulatory motifs. Antioxid Redox Signal 3: 685-696 10.1089/15230860152543023 [doi].
44. McCoubrey WK Jr, Huang TJ, Maines MD, (1997) Heme oxygenase-2 is a hemoprotein and binds heme through heme regulatory motifs that are not involved in heme catalysis. J Biol Chem 272: 12568-12574.
45. Qi Z, Hamza I, O'Brian MR, (1999) Heme is an effector molecule for iron-dependent degradation of the bacterial iron response regulator (Irr) protein. Proc Natl Acad Sci U S A 96: 13056-13061.
46. Yi L, Ragsdale SW, (2007) Evidence that the heme regulatory motifs in heme oxygenase-2 serve as a thiol/disulfide redox switch regulating heme binding. J Biol Chem 282: 21056-21067.
47. Yi L, Jenkins PM, Leichert LI, Jakob U, Martens JR, et al. (2009) Heme regulatory motifs in heme oxygenase-2 form a thiol/disulfide redox switch that responds to the cellular redox state. J Biol Chem 284: 20556-20561 M109.015651 [pii];10.1074/jbc.M109.015651 [doi].
48. Gardner JD, Yi L, Ragsdale SW, Brunold TC, (2010) Spectroscopic insights into axial ligation and active-site H-bonding in substrate-bound human heme oxygenase-2. J Biol Inorg Chem 15: 1117-1127 10.1007/s00775-010-0672-8 [doi].
49. Gottlieb HE, Kotlyar V, Nudelman A, (1997) NMR Chemical Shifts of Common Laboratory Solvents as Trace Impurities. J Org Chem 62: 7512-7515.
50. Vreman HJ, Stevenson DK, (1988) Heme oxygenase activity as measured by carbon monoxide production. Anal Biochem 168: 31-38.
51. Cook MN, Nakatsu K, Marks GS, McLaughlin BE, Vreman HJ, et al. (1995) Heme oxygenase activity in the adult rat aorta and liver as measured by carbon monoxide formation. Can J Physiol Pharmacol 73: 515-518.
52. Kabsch W, (2010) XDS. Acta Crystallogr D Biol Crystallogr 66: 125-132 S0907444909047337 [pii];10.1107/S0907444909047337 [doi].
53. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al. (2007) Phaser crystallographic software. J Appl Crystallogr 40: 658-674 10.1107/S0021889807021206 [doi].
54. Collaborative Computational Project N4 (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50: 760-763.
55. Schuttelkopf AW, van Aalten DM, (2004) PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 60: 1355-1363.
56. Emsley P, Cowtan K, (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132.
57. Murshudov GN, Vagin AA, Dodson EJ, (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53: 240-255 10.1107/S0907444996012255 [doi];S0907444996012255 [pii].
58. Krissinel E, Henrick K, (2004) Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr D Biol Crystallogr 60: 2256-2268 S0907444904026460 [pii];10.1107/S0907444904026460 [doi].
59. Laskowski RA, MacArthur MW, Moss DS, Thornton JM, (1993) PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr 26: 283-291.
60. DeLano WL, (2002) The PyMOL Molecular Graphics System version Palo Alto, CA, USA DeLano Scientific.